N-((3R,4S)-1-Benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine

Catalog No. :
ACWNBX012
CAS No. :
1092578-45-4
Molecular Formula :
C20H25N5
Molecular Weight :
335.45

IUPAC Name:N-((3R,4S)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine

N-((3R,4S)-1-Benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN-((3R,4S)-1-Benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
IUPAC NameN-((3R,4S)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
Molecular FormulaC20H25N5
Molecular Weight335.45
SMILESCN([C@H]1CN(CC2=CC=CC=C2)CC[C@@H]1C)C3=C4C(NC=C4)=NC=N3
InChI KeyUMWNXPTXDOVDFE-YJBOKZPZSA-N
SynonymN-((3R,4S)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine;Tofacitinib Impurity 130;Tofatinib Impurity 22;N-((3R,4S)-1-Benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (Tofacitinib Impurity);7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[(3R,4S)-4-methyl-1-(phenylmethyl)-3-piperidinyl]-
CAS No.1092578-45-4

Synthetic Route by SureRoute

1. ACWNBX012 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACFYWU907 route compound structure diagram
    ACFYWU9073680-69-1 In Stock
  4. Then
  5. ACWNBX012 route product structure diagram
    ACWNBX0121092578-45-4
Inquiry

2. ACWNBX012 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACWNBX012 route product structure diagram
    ACWNBX0121092578-45-4
Inquiry

Comments (0)